Yüklüyor......
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes
Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European...
Kaydedildi:
| Yayımlandı: | Eur J Cancer |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844000/ https://ncbi.nlm.nih.gov/pubmed/26875112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.12.022 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|